OJRD  Vol.2 No.2 , May 2012
Mortality-Related Risk Factors in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment
Abstract: Background: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious diseases with similar pathophysiologic aspects. The prognosis of patients with these conditions is highly uncertain, particularly incident cases. Methods: A Cox proportional hazards model was applied to a group of 85 patients (81% women, mean age 52 (18 - 82) years) with PAH (80%) and non-surgical CTEPH (20%) to evaluate risk factors for mortality. The following variables were included in the model: age, etiology, baseline 6-minute walk test (6 mWT), cardiac index, and improvement in the 6 mWT following initiation of first medical treatment. Results: In the multivariate analysis, the response to treatment, assessed by an improvement on the 6 mWT, was the most relevant prognostic factor in these patients (RR, 4.832 (95% CI, 1.888 - 12.364); p = 0.001). The remaining variables studied in this model had less influence on the prognosis: age > 50 years (RR, 0.744 (95% CI, 0.26 - 2.133); p = 0.582); etiology of connective tissue disease-associated PAH (RR, 3.145 (95% CI, 0.995-9.946); p = 0.051) or CTEPH (RR, 0.654 (95% CI, 0.179 - 2.387); p = 0.521) with respect to idiopathic PAH; baseline 6 mWT (RR, 1.173 (95% CI, 0.599 - 4.895); p = 0.315); or cardiac index (RR, 2.295 (95% CI, 0.793 - 6.642); p = 0.125). Conclusions: There is a high degree of uncer-tainty regarding the prognosis of PAH and CTEPH at the start of appropriate treatment. Our results support the idea that the initial treatment response is of paramount importance as prognostic factor in these patients.
Cite this paper: M. Lopez-Meseguer, R. Aguilar, C. Bravo, V. Monforte, L. Dos, C. Simeon, E. Domingo and A. Roman, "Mortality-Related Risk Factors in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment," Open Journal of Respiratory Diseases, Vol. 2 No. 2, 2012, pp. 17-24. doi: 10.4236/ojrd.2012.22003.

[1]   A. E. Frost, D. B. Badesch, R. J. Barst, R. L. Benza, C. G. Elliott, H. W. Farber, et al., “The Changing Picture of Patients with Pulmonary Arterial Hypertension in the United States: How REVEAL Differs from Historic and Non-US Contemporary Registries,” Chest, Vol. 139, No. 1, 2011, pp. 128-137. doi:10.1378/chest.10-0075

[2]   G. E. D’Alonzo, R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, et al., “Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry,” Annals of Internal Medicine, Vol. 115, No. 5, 1991, pp. 343-349.

[3]   V. Pengo, A. W. Lensing, M. H. Prins, A. Marchiori, B. L. Davidson, F. Tiozzo, et al., “Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism,” The New England Journal of Medicine, Vol. 350, No. 22, 2004, pp. 2257-2264. doi:10.1056/NEJMoa032274

[4]   D. Poli, E. Grifoni, E. Antonucci, C. Arcangeli, D. Prisco, R. Abbate, et al., “Incidence of Recurrent Venous Thromboembolism and of Chronic Thromboembolic Pulmonary Hypertension in Patients after a First Episode of Pulmonary Embolism,” Journal of Thrombosis Thrombolysis, Vol. 30, No. 3, 2010, pp. 294-299. doi:10.1007/s11239-010-0452-x

[5]   C. Becattini, G. Agnelli, R. Pesavento, M. Silingardi, R. Poggio, M. R. Taliani, et al., “Incidence of Chronic Thromboembolic Pulmonary Hypertension after a First Episode of Pulmonary Embolism,” Chest, Vol. 130, No. 1, 2006, pp. 172-175. doi:10.1378/chest.130.1.172

[6]   D. B. Badesch, H. C. Champion, M. A. Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, et al., “Diagnosis and Assessment of Pulmonary Arterial Hypertension,” Journal of the American College of Cardiology, Vol. 54, No. 1, 2009, pp. S55-S66. doi:10.1016/j.jacc.2009.04.011

[7]   O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, et al., “Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension: Prognostic Factors and Survival,” Journal of the American College of Cardiology, Vol. 40, No. 4, 2002, pp. 780-788. doi:10.1016/S0735-1097(02)02012-0

[8]   V. V. McLaughlin, A. Shillington and S. Rich. “Clinical Investigation and Reports Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy,” Circulation, Vol. 106, No. 12, 2002, pp. 1477-1482. doi:10.1161/01.CIR.0000029100.82385.58

[9]   N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, et al., “Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension,” European Respiratory Journal, Vol. 34, No. 6, 2009, pp. 1219-1263. doi:10.1183/09031936.00139009

[10]   N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani and A. Branzi, “A Meta-Analysis of Randomized Controlled Trials in Pulmonary Arterial Hypertension,” European Heart Journal, Vol. 30, No. 4, 2009, pp. 394-403. doi:10.1093/eurheartj/ehp022

[11]   A. Macchia, R. Marchioli, G. Tognoni, M. Scarano, R. Marfisi, L. Tavazzi, et al., “Systematic Review of Trials Using Vasodilators in Pulmonary Arterial Hypertension: Why a New Approach Is Needed,” American Heart Journal, Vol. 159, No. 2, 2010, pp. 245-257. doi:10.1016/j.ahj.2009.11.028

[12]   V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, et al., “Prognosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines,” Chest, Vol. 126, No. 1, 2004, pp. 78S-92S. doi:10.1378/chest.126.1_suppl.78S

[13]   S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky and S. E. Kimmel, “Hemodynamics and Survival in Patients with Pulmonary Arterial Hypertension Related to Systemic Sclerosis,” Chest, Vol. 123, No. 2, 2003, pp. 344-350. doi:10.1378/chest.123.2.344

[14]   V. McLaughlin, M. Humbert, G. Coghlan, P. Nash and V. Steen, “Pulmonary Arterial Hypertension: The Most Devastating Vascular Complication of Systemic Sclerosis,” Rheumatology, Vol. 48, No. 3, 2009, pp. iii25-iii31. doi:10.1093/rheumatology/kep107

[15]   S. C. Mathai, L. K. Hummers, H. C. Champion, F. M. Wigley, A. Zaiman, P. M. Hassoun, et al., “Survival in Pulmonary Hypertension Associated with the Scleroderma Spectrum of Diseases: Impact of Interstitial Lung Disease,” Arthritis and Rheumatism, Vol. 60, No. 2, 2009, pp. 569-577. doi:10.1002/art.24267

[16]   S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki, M. Fujita, et al., “Clinical Correlates and Prognostic Significance of Six-Minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing,” American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 2, 2000, pp. 487-492.

[17]   P. E. Subias, M. J. Cano and A. Flox, “Medical Treatment in Patients with Chronic Thromboembolic Pulmonary Hypertension,” Archivos De Bronconeumologia, Vol. 45. No. 6, 2009, pp. 35-39.

[18]   X. Jais, A. M. D’Armini, P. Jansa, A. Torbicki, M. Delcroix, H. A. Ghofrani, et al., “Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of ChronIc Thromboembolic Pulmonary Hypertension), a Randomized, Placebo-controlled Trial,” Journal of the American College of Cardiology, Vol. 52, No. 25, 2008, pp. 2127-2134.

[19]   H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, et al., “Inhaled Iloprost for Severe Pulmonary Hypertension,” The New England Journal of Medicine, Vol. 347, No. 5, 2002, pp. 322-329. doi:10.1056/NEJMoa020204